Skip to main content

Table 1 GSK-3β dephosphorylation

From: Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling

Treatment Experiment Experiment 1-5
1 2 3 4 5 AVG of [[1]] -[[2]] (±SD)
DMSO 1.06 0.91 0.96   
ut 1.00 1.00 1.00 1.00 1.00
2 h TQ 0.90 0.87 0.66 0.47  
PI3K-inh. 0.69 0.84 0.86 0.57
[1] TQ + PI3K-inh. 0.61 0.47 0.46 0.41  
[2] Multiplication of TQxPI3K-Inh. 0.61 0.73 0.56 0.27  
Difference[1] -[2] at 2 h −0.01 −0.26 −0.10 0.15   −0.06 (±0.17)*
4 h TQ 0.93 1.07 0.76   0.92  
PI3K inh. 0.67 1.04 0.64 0.69
[1] TQ + PI3K inh. 0.59 0.53 0.47 0.62
[2] Multiplication of TQxPI3K-Inh. 0.62 1.11 0.49 0.63
Difference[1] -[2] at 4 h −0.03 −0.59 −0.02   −0.01 −0.16 (±0.28)**
  1. RKO cells were treated with TQ, PI3K inhibitor or with a combination of both substances for 2 h or 4 h to test for syngergistic or additive effects on the dephosphorylation of GSK-3β. 5 different Western blots were performed and the relative ratios of p-GSK-3β and total GSK-3β protein levels were calculated using the program Image J. Mathematically, when effects are measured as proportions, the additive effect of two substances is the multiplication of the two values resulting from the single treatments. The mathematical product of both treatments is only minimally deviating from the actual values for the double treatment resulting from the Western blots. The null-hypothesis of no mean difference cannot be rejected at either time point (T-test, p-value *0.56 (2 h) and **0.34 (4 h)). While this result is in itself no proof of additivity, a closer inspection of the calculated differences shows that the assumption of additivity is indeed reasonable: In experiments 1, 3 and 5 the differences are very close to zero. Experiments 2 and 5 show stronger deviations, however in opposite directions and the resulting mean differences are close to zero for both time points.